---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-24-000050"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2024-06-10T23:59:59+00:00"
generated_at: "2026-06-01T05:20:32.759002+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Allogene appoints new principal accounting officer; shareholders elect directors and ratify auditor

## Summary
- Annie Yoshiyama appointed principal accounting officer, replacing Geoffrey Parker; Parker remains CFO.
- Yoshiyama previously VP Finance & Controller at AN2 Therapeutics and CAO at Tricida.
- Shareholders elected four Class III directors (DeYoung, Humer, Kazam, Mayo) to serve until 2027.
- Advisory say-on-pay approved with 119.7M votes for, 16.3M against.
- Ernst & Young ratified as independent auditor for fiscal year ending December 31, 2024.

## SEC filing metadata
- accession: 0001737287-24-000050
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2024-06-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000050/0001737287-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000050/allo-20240605.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-24-000050
- JSON: https://secwatch.observer/filing/0001737287-24-000050.json
- Plain text: https://secwatch.observer/filing/0001737287-24-000050.txt

## Key facts
- Executive change
  Geoffrey Parker changed role as principal accounting officer at Allogene Therapeutics, Inc..
  - Action: replaced
  - Role: principal accounting officer
  source text: Mr. Parker continues to serve as the Company’s Chief Financial Officer and principal financial officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000050/0001737287-24-000050-index.htm
- Executive change
  Annie Yoshiyama was appointed as principal accounting officer at Allogene Therapeutics, Inc..
  - Action: appointed
  - Role: principal accounting officer
  source text: appointed Annie Yoshiyama, the Company’s current Senior Vice President and Corporate Controller, as the Company’s principal accounting officer, effective immediately, replacing Geoffrey Parker in such capacity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737287/000173728724000050/0001737287-24-000050-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.